Aztreonam for Inhalation Solution (AZLI) for the Treatment of Exacerbations of Cystic Fibrosis
Status:
Completed
Trial end date:
2019-09-01
Target enrollment:
Participant gender:
Summary
This study evaluates the role of AZLI in the treatment of acute pulmonary exacerbations of
CF. For consecutive exacerbations patients will receive AZLI + IV Colistin, or two IV
anti-pseudomonals.
Phase:
Phase 4
Details
Lead Sponsor:
Liverpool Heart and Chest Hospital NHS Foundation Trust